In a regulatory filing, Vertex Pharmaceuticals CSO David Altshuler disclosed the sale of 3,002 common shares of the company on February 21 at a price of $421.77 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRTX:
- Crispr Therapeutics price target raised to $112 from $110 at Chardan
- A New Cause for Concern: Vertex Pharmaceuticals Inc. Adds a New Regulation Risk
- Vertex Pharmaceuticals initiated with an Outperform at Wolfe Research
- Vertex Pharmaceuticals COO Arbuckle sells over $1.8M in shares
- Vertex announces EC grants conditional marketing authorization to Casgevy
